Bioatla Inc (BCAB) Stock Price, Quote & News

Company Profile

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and squamous cell carcinoma o...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 558 0708

Fax: 858 558 0709

Website: www.bioatla.com

Address:

11085 Torreyana Road, San Diego, United States

jaehoony Aug. 8 at 7:14 AM

$BCAB We continue to advance partnering discussions across our preclinical and clinical CAB portfolio and remain confident in our goal to close at least one transaction in 2025

1 · Reply

Henry_RatBastard_Hill Aug. 8 at 1:48 AM

$PHGE $BCAB $RVPH $ADIL

1 · Reply

jaehoony Aug. 8 at 1:18 AM

$BCAB “We are making encouraging progress with a partner at the term-sheet stage for one of our CAB assets, while continuing to advance partnering discussions across our portfolio, allowing us to maintain our guidance for a transaction this year.”

0 · Reply

3SSA Aug. 7 at 10:24 PM

$BCAB Summary of BioAtla, Inc. Q2 2025 Earnings Call BioAtla, Inc. held its Q2 2025 earnings call on August 7, 2025, at 4:30 PM Eastern Time. Key points from the announcement include: 1. Clinical Progress: • BA3182 (CAB-EpCAM x CAB-CD3 Bispecific T-cell Engager): Phase 1 dose-escalation study ongoing (1.2 mg cohort), showing tumor reduction in seven patients with advanced cancers (pancreatic, colorectal, breast, cholangiocarcinoma, and NSCLC). Data readout expected in 2H 2025, with cohort expansion data in 1H 2026. • Ozuriftamab Vedotin (Oz-V; CAB-ROR2-ADC): Phase 2 study in treatment-refractory SCCHN shows strong efficacy in HPV+ oropharyngeal squamous cell carcinoma (45% response rate, 100% disease control rate). FDA meeting planned for Q3 2025 to discuss Phase 3 design, with potential for accelerated approval. 2. Partnerships: • Ongoing partnership discussions across clinical and preclinical portfolios, with confidence in closing at least one deal in 2025.

1 · Reply

winners18 Aug. 7 at 9:58 PM

$BCAB earning call at 12 : 44 upcoming epcam data may be apotential transformational value creation event to the shareholder. We just need patience and read the tea leaves.

0 · Reply

eruizgon Aug. 7 at 9:54 PM

$BCAB info about the call?

0 · Reply

HjalmarTheGreat Aug. 7 at 9:48 PM

$BCAB I feel good about the call.

1 · Reply

dudereally Aug. 7 at 8:57 PM

$BCAB I jumped in at the very end of the call and he said kind of mumble something about the partnership for phase 2 asset?

2 · Reply

jaehoony Aug. 6 at 9:01 PM

$BCAB BA3021 with BMS?

0 · Reply

KokoKosta Aug. 6 at 6:10 PM

$BCAB nasdaq?

1 · Reply

BioAtla, Inc. (BCAB) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:05 PM EDT - 3 days ago

BioAtla Reports Second Quarter 2025 Financial Results and Highlights Recent Progress

Aug 4, 2025, 8:00 AM EDT - 6 days ago

BioAtla to Announce Second Quarter 2025 Financial Results and Provide Business Highlights on August 7, 2025

Jul 17, 2025, 8:00 AM EDT - 24 days ago

BioAtla Announces Upcoming Oral Presentation at the 2025 European Society for Medical Oncology (ESMO) TAT Asia Meeting

$BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress$

Jul 3, 2025, 8:00 AM EDT - 5 weeks ago

BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress

Jun 2, 2025, 8:00 AM EDT - 2 months ago

BioAtla Presents Phase 2 Ozuriftamab Vedotin (Oz-V) Clinical Trial Data Demonstrating Compelling Antitumor Activity in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC) at the 1.8 mg/kg Q2W dosing regimen

May 6, 2025, 5:55 PM EDT - 3 months ago

BioAtla, Inc. (BCAB) Q1 2025 Earnings Call Transcript

May 6, 2025, 4:05 PM EDT - 3 months ago

BioAtla Reports First Quarter 2025 Financial Results and Highlights Recent Progress

Apr 30, 2025, 8:00 AM EDT - 3 months ago

BioAtla to Participate in the Citizens Life Sciences Conference

Apr 29, 2025, 8:00 AM EDT - 3 months ago

BioAtla to Announce First Quarter 2025 Financial Results and Provide Business Highlights on May 6, 2025

Apr 24, 2025, 8:00 AM EDT - 3 months ago

BioAtla Announces Poster Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Apr 23, 2025, 10:05 AM EDT - 3 months ago

BioAtla Announces Upcoming Poster Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Mar 27, 2025, 6:18 PM EDT - 4 months ago

BioAtla, Inc. (BCAB) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 5:05 PM EDT - 4 months ago

BioAtla Cuts 30% of Jobs in Restructuring Effort

Mar 27, 2025, 4:05 PM EDT - 4 months ago

BioAtla Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress

Mar 20, 2025, 8:00 AM EDT - 5 months ago

BioAtla Announces Two Poster Presentations at Upcoming Medical Meetings

Mar 19, 2025, 8:00 AM EDT - 5 months ago

BioAtla to Announce Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Highlights on March 27, 2025

Mar 4, 2025, 7:34 AM EST - 5 months ago

AXL Inhibitors Pipeline Research Report 2025: Features Insights on 16+ Companies and 20+ Pipeline Drugs, Including Cabozantinib (Exelixis/Ipsen), BA 3011 (BioAtla) & TP-0903 (Sumitomo Dainippon Pharma Oncology)

Dec 20, 2024, 9:00 AM EST - 8 months ago

BioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection Points

Dec 16, 2024, 8:00 AM EST - 8 months ago

BioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting

Dec 10, 2024, 8:00 AM EST - 8 months ago

BioAtla Announces Upcoming Poster Presentation at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting

Nov 9, 2024, 8:53 AM EST - 9 months ago

BioAtla, Inc. (BCAB) Q3 2024 Earnings Call Transcript

Oct 8, 2024, 6:12 AM EDT - 10 months ago

BioAtla's FDA Fast-Tracked Drug Candidate Boosts Its Oncology Prospects, Speculative Buy

Oct 7, 2024, 11:29 AM EDT - 10 months ago

BioAtla: Numerous Catalysts Coming In Q4

Oct 4, 2024, 9:05 AM EDT - 11 months ago

BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting

Oct 1, 2024, 8:00 AM EDT - 11 months ago

BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress

Sep 23, 2024, 7:30 AM EDT - 11 months ago

BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody

Aug 11, 2024, 1:32 AM EDT - 1 year ago

BioAtla, Inc. (BCAB) Q2 2024 Earnings Call Transcript

Jul 25, 2024, 5:39 PM EDT - 1 year ago

BioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D Day

May 29, 2024, 8:00 AM EDT - 1 year ago

BioAtla to Participate in the Jefferies Global Healthcare Conference

May 23, 2024, 5:05 PM EDT - 1 year ago

BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

May 14, 2024, 8:35 PM EDT - 1 year ago

BioAtla, Inc. (BCAB) Q1 2024 Earnings Call Transcript

May 14, 2024, 4:05 PM EDT - 1 year ago

BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent Progress

May 8, 2024, 8:00 AM EDT - 1 year ago

BioAtla to Participate in the Citizens JMP Life Sciences Conference

May 7, 2024, 8:00 AM EDT - 1 year ago

BioAtla to Announce First Quarter 2024 Financial Results and Provide Business Highlights on May 14, 2024

May 6, 2024, 8:00 AM EDT - 1 year ago

BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors

May 2, 2024, 10:03 AM EDT - 1 year ago

BioAtla: A Buried ADC Concern Gets Some New Life In 2024

Apr 24, 2024, 4:35 PM EDT - 1 year ago

BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Mar 26, 2024, 7:21 PM EDT - 1 year ago

BioAtla, Inc. (BCAB) Q4 2023 Earnings Call Transcript

Mar 26, 2024, 4:01 PM EDT - 1 year ago

BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress

Mar 19, 2024, 8:00 AM EDT - 1 year ago

BioAtla to Announce Fourth Quarter and Full-Year 2023 Financial Results and Provide Business Highlights on March 26, 2024

Mar 7, 2024, 8:00 AM EST - 1 year ago

BioAtla Announces Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Dec 20, 2023, 8:00 AM EST - 1 year ago

BioAtla to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Dec 13, 2023, 8:00 AM EST - 1 year ago

BioAtla Hosting Virtual R&D Day to Highlight BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types

Dec 6, 2023, 8:00 AM EST - 1 year ago

BioAtla to Host Virtual R&D Day to Review BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types on Wednesday, December 13, 2023

Dec 5, 2023, 8:00 AM EST - 1 year ago

BioAtla Presented Phase 2 Clinical Trial Data at the IASLC 2023 North America Conference on Lung Cancer and Virtual KOL Event

Nov 30, 2023, 8:00 AM EST - 1 year ago

BioAtla to Participate in the JMP Securities Hematology and Oncology Summit

Nov 28, 2023, 8:00 AM EST - 1 year ago

BioAtla to Host Virtual KOL Event to Review IASLC Data on BA3011 in NSCLC

Nov 12, 2023, 5:38 AM EST - 1 year ago

BioAtla, Inc. (BCAB) Q3 2023 Earnings Call Transcript

Nov 7, 2023, 4:01 PM EST - 1 year ago

BioAtla Reports Third Quarter 2023 Financial Results and Highlights Recent Progress

jaehoony Aug. 8 at 7:14 AM

$BCAB We continue to advance partnering discussions across our preclinical and clinical CAB portfolio and remain confident in our goal to close at least one transaction in 2025

1 · Reply

Henry_RatBastard_Hill Aug. 8 at 1:48 AM

$PHGE $BCAB $RVPH $ADIL

1 · Reply

jaehoony Aug. 8 at 1:18 AM

0 · Reply

3SSA Aug. 7 at 10:24 PM

1 · Reply

winners18 Aug. 7 at 9:58 PM

$BCAB earning call at 12 : 44 upcoming epcam data may be apotential transformational value creation event to the shareholder. We just need patience and read the tea leaves.

0 · Reply

eruizgon Aug. 7 at 9:54 PM

$BCAB info about the call?

0 · Reply

HjalmarTheGreat Aug. 7 at 9:48 PM

$BCAB I feel good about the call.

1 · Reply

dudereally Aug. 7 at 8:57 PM

$BCAB I jumped in at the very end of the call and he said kind of mumble something about the partnership for phase 2 asset?

2 · Reply

jaehoony Aug. 6 at 9:01 PM

$BCAB BA3021 with BMS?

0 · Reply

KokoKosta Aug. 6 at 6:10 PM

$BCAB nasdaq?

1 · Reply

UncleGs Aug. 6 at 5:21 PM

$BCAB Better get it while you can. Stay Patient My Friends! Latest Report 08/05/2025 LSEG maintains a current price target of $5.5 for BCAB Just sayin!

0 · Reply

Drugtrade Aug. 5 at 7:51 PM

$BCAB this has reverse split written all over it they should just forego the extension and get it over with

0 · Reply

asdfadfsadsafdfassdf Aug. 5 at 1:28 PM

$BCAB

0 · Reply

HjalmarTheGreat Aug. 5 at 1:18 PM

$BCAB I am heavily invested here. The "Hopium" crap is a load of BS. No one would invest in any stock without "hoping" it will go up and bring in the money. Those who are long here are primarily bio investors who see potential in the pipeline. It's that simple. We'll see what Thursday brings. Fingers crossed for a better financial profile, extension news, and clinical updates.

0 · Reply

asdfadfsadsafdfassdf Aug. 4 at 9:38 PM

$BCAB

0 · Reply

beentherebefor Aug. 4 at 9:34 PM

$BCAB Will we see a 180 day extension tomorrow?

0 · Reply

DON_VTOL Aug. 1 at 6:09 PM

$BCAB what a joke!

0 · Reply

SDBiotechInvestor Aug. 1 at 4:48 PM

$BOLT Never invest for partnerships. Biotech investing 101. $BCAB had "term sheets" and also promised multiple deals. Guess what nothing ever happened. This will be 50% lower by December.

1 · Reply

Pharma_Stock_Calls Jul. 29 at 3:03 PM

✅ 💊 $BCAB Entry: $0.3650 → Target: $0.4497

0 · Reply

HjalmarTheGreat Jul. 29 at 12:54 PM

$BCAB We should see the quarterly report sometime between now and the 8th of August. If I were a betting man I'd say we get some piggyback news. Whether it's before or after we see the report is anyone's guess. We will know soon enough. Either way the end is near.

0 · Reply

HjalmarTheGreat Jul. 28 at 2:01 PM

$BCAB Good luck with abp and rvph. Still waiting here for news.

0 · Reply

zpepzp Jul. 25 at 6:38 PM

$BCAB 버거들아 얼른 올려라, 곧 LO 나온다잉

0 · Reply

Market Cap	20.60M
Revenue (ttm)	11.00M
Net Income (ttm)	-69.78M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-634.36%
Debt to Equity Ratio	0.00

Volume	510,800
Avg Vol	665,142
Day's Range	N/A - N/A
Shares Out	58.42M
Stochastic %K	43%
Beta	0.90
Analysts	Strong Sell
Price Target	$8.33